Answers are grounded in this paper and cite their sources.
Randomized trial examines early glycemic deterioration in thyroid eye disease patients, suggesting a baseline model for risk prediction.
Introduction and Objective: Insulin-like growth factor-1 receptor (IGF-1R) inhibitor has been developed as an effective therapy for thyroid eye disease (TED). However, treatment-associated hyperglycemia remains a clinical concern. We aimed to examine whether early glycemic deterioration during IGF-1R inhibitor therapy is associated with subsequent glycemic trajectories and to develop and validate a risk prediction model. Methods: We analyzed data from three independent randomized clinical trials of the IGF-1R inhibitor IBI311 for TED, including 129 participants treated with IBI311. Two trials served as training cohort (n=76), and the remaining trial served as an independent validation cohort (n=53). Early glycemic deterioration was defined as a ≥0.5% increase in HbA1c by week 6 or initiation/intensification of glucose-lowering therapy within 6 weeks. Associations between early deterioration and glycemic outcomes at treatment completion (24 weeks) were examined in training cohort. A prediction model was developed using baseline metabolic variables with elastic net-regularized logistic regression and externally validated. Results: Early glycemic deterioration occurred in 18.6% (14/129) of participants. Individuals with early deterioration experienced greater increases in HbA1c (1.13% ± 0.55% vs. 0.17% ± 0.33%; P=0.001) and FBG (1.86 ± 1.79 mmol/L vs. 0.16 ± 0.61 mmol/L; P=0.021) at 24 weeks. At baseline, participants with early deterioration had higher FBG, blood pressure, lower HDL-c, and greater metabolic syndrome (MetS) score. An elastic net model incorporating baseline FBG (standard β=0.25) and MetS score (standard β=0.20) demonstrated good discrimination for early deterioration (external AUC 0.80, 95% CI 0.63-0.94). Conclusion: Early glycemic deterioration during IGF-1R inhibitor therapy is associated with subsequent hyperglycemia. A simple baseline model using routinely available metabolic measures may enable early risk stratification.
No takes yet. Share an insight, caveat, or question.
(14321) et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: